HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rizvi, S. A. Articles by Fox, E. J. Search for Related Content PubMed PubMed Citation Articles by Rizvi, S. A. Articles by Fox, E. J.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Mitoxantrone for multiple sclerosis in clinical practice

From the Department of Clinical Neurosciences, Brown University, Providence, Rhode Island (Dr. Rizvi), Doctors’ Hospital, Coral Gables, Florida (Dr. Zwibel), and the MS Clinic of Central Texas, Round Rock, Texas (Dr. Fox).

Address correspondence and reprint requests to Dr. Syed Rizvi, Brown University, Department of Clinical Neurosciences, 2 Dudley Street, Suite 555, Providence, RI 02905; e-mail: srizvi{at}lifespan.org

Patients with worsening relapsing–remitting multiple sclerosis (MS), secondary progressive MS, and progressive relapsing MS are potential candidates for treatment with mitoxantrone. Early identification of these patients is essential because there is emerging evidence that early and aggressive treatment might delay or limit long-term disability. Treatment with mitoxantrone is associated with certain adverse events, such as cardiotoxicity. However, the possible benefits of treatment (e.g., reduction in disease progression) outweigh the risks for patients with aggressive or worsening disease. With the selection of appropriate patients and careful monitoring for adverse events, mitoxantrone can be safely administered.

This article has been cited by other articles:

				E. Cocco, P. Marchi, C. Sardu, P. Russo, A. Paolillo, M. Mascia, M. Solla, J. Frau, L. Lorefice, S. Massole, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 975 - 980. [Abstract] [PDF]